WAT|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $4.00 | - | - |
| Q2'26 | $3.99 | $3.05 | -23.6% |
| Q1'26 | $2.36 | $2.70 | +14.4% |
| Q4'25 | $2.47 | $4.53 | +83.1% |
| Q3'25 | $3.22 | $3.40 | +5.5% |
| Q2'25 | $2.94 | $2.95 | +0.3% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $1.8B | - | - |
| Q2'26 | $1.6B | $1.6B | +0.4% |
| Q1'26 | $1.2B | $1.3B | +4.3% |
| Q4'25 | $712M | $932M | +31.0% |
| Q3'25 | - | $800M | - |
| Q2'25 | - | $771M | - |
Market Data
WAT Stock Snapshot
WAT is currently trading at $410.75, giving Waters Corporation a market cap of 40.86B and a P/E ratio of 245.9. Today's range spans $410.75–$410.75, with shares opening at $410.75 and moving up $0.00 (0.0%) from the prior close. DailyIQ's technical score sits at 82/100 (BUY).
Over the past year WAT has traded between $282.77 and $421.74 - the current price is +45.3% off the 52-week low and -2.6% from the high.
Waters Corporation (WAT) is a large-cap in Healthcare with 40.86B in market cap, and the current setup is one of the cleaner bullish reads in the space. Technical score: 82/100 (BUY). Sentiment: neutral at -/100. Price: $410.75 (near 52-week highs). The current P/E ratio stands at 245.9. The 52-week range of $282.77–$421.74 provides structural context - and the current technical/sentiment alignment is the type of setup that attracts both momentum and growth-oriented capital.
Earnings revision cycles in large-cap Healthcare names tend to compound: when technicals confirm a BUY thesis (82/100) and news sentiment (-/100, neutral) supports the narrative, analyst upgrades follow price rather than lead it. At $410.75 (near 52-week highs), WAT's position within the $282.77–$421.74 annual range suggests there's room for multiple expansion before the stock encounters meaningful technical resistance.
Company Insights: Waters Corporation (WAT)
Waters Corporation’s share price sits at $406.86, a mere 2.1% below its 52‑week high of $414.15, indicating a modest compression cushion. The current valuation of 236.22× forward earnings places the stock well above the diagnostics peer average of 53.0. Analyst consensus targets the price at $433.39, implying roughly 6.5% upside from today before the premium compresses. The company’s market cap of $39.2bn reflects the high multiples investors assign to its growth prospects. With a 25.3% return from the 52‑week low, the stock remains attractive for value‑oriented investors seeking mean‑reversion opportunities.
Q1 2026 revenue surged to $1.267bn, a 91.5% year‑on‑year jump, underscoring robust demand for liquid chromatography solutions. The subsequent Q2 2026 revenue of $1.645bn exceeded estimates by $6m, confirming sustained growth momentum. However, Q2 EPS of $3.05 fell short of the $3.99 forecast, reflecting a mixed earnings trajectory. Nonetheless, the company maintained a 3.4% EPS increase from Q1, demonstrating resilient margin management. Revenue beats in recent quarters reinforce confidence in continued demand for its analytical platforms.
Sentiment score of 66 on a 100‑point scale indicates generally positive market perception, though recent delta of -1 suggests a slight cooling. Stable sentiment trend over the past 14 days aligns with the steady share price movement within the 52‑week range. Analyst upgrades from TD Cowen and Goldman Sachs, coupled with JPMorgan’s target adjustment to $400, reinforce a bullish outlook. The company’s disciplined capital return program, allocating over $90m annually to buybacks and dividends, supports shareholder value. Price returns over the past year stand at 8.1%, outpacing many peers in the diagnostics sector.
Waters’ Xevo TQ Absolute XR IVD launch expands its clinical laboratory portfolio, challenging competitors like Agilent and Abbott. The integrated workflow solutions covering chromatography, mass spectrometry, and thermal analysis create a differentiated value proposition. Strategic acquisitions and service contracts further cement its position as a preferred vendor for drug discovery and environmental testing. Product innovation, including next‑generation ion mobility modules and AI‑driven data processing tools, positions the firm for future market leadership. Monitoring quarterly earnings releases and margin updates will clarify the sustainability of the current growth trajectory.
Valuation Premium
Waters trades at a forward P/E of 236.22, roughly 4.5× its peer average of 53.0 across the diagnostics sector.
This premium reflects the market's confidence in continued top‑line expansion and high‑margin instrumentation.
The analyst consensus target of $433.39 sits 6.5% above the current level, indicating modest upside before the valuation compresses.
Revenue Momentum
Q1 2026 revenue climbed to $1.267bn, a 91.5% year‑on‑year jump, underscoring robust demand for liquid chromatography solutions.
The subsequent Q2 2026 revenue of $1.645bn surpassed estimates by $6m, demonstrating sustained growth momentum.
Year‑over‑year revenue growth of 46.9% in Q4 2025 and 91.5% in Q1 2026 positions Waters as a high‑growth play within healthcare analytics.
Profitability Resilience
EPS in Q1 2026 reached $2.70, beating the $2.36 estimate, while Q2 2026 EPS of $3.05 fell short of the $3.99 forecast.
Despite the Q2 miss, the company maintained a 3.4% EPS increase from Q1, reflecting resilient margin management.
Consistent revenue beats and a strong operating cash flow base provide a buffer against commodity price swings.
Market Sentiment
Sentiment score of 66 on a 100‑point scale indicates generally positive market perception, though recent delta of -1 suggests a slight cooling.
Stable sentiment trend over the past 14 days aligns with the steady share price movement within the 52‑week range.
Analyst upgrades from TD Cowen and Goldman Sachs, coupled with JPMorgan’s target adjustment to $400, reinforce a bullish outlook.
Competitive Position
Waters’ Xevo TQ Absolute XR IVD launch expands its clinical laboratory portfolio, challenging competitors like Agilent and Abbott.
The company’s integrated workflow solutions cover chromatography, mass spectrometry, and thermal analysis, creating a differentiated value proposition.
Strategic acquisitions and service contracts further cement its position as a preferred vendor for drug discovery and environmental testing.
Product Innovation
The Xevo TQ Absolute XR IVD platform delivers unprecedented sensitivity and speed, meeting the evolving needs of high‑throughput clinical labs.
Waters’ continuous investment in software and analytics enhances data integration across its instrumentation suite.
Innovation pipeline includes next‑generation ion mobility modules and AI‑driven data processing tools.
Capital Allocation
Waters maintains a disciplined capital return program, allocating over $90m annually to buybacks and dividends.
The company’s market cap of $39.2bn supports a sustainable payout ratio while preserving growth capital.
Capital deployment decisions are guided by cash flow forecasts and the potential for strategic acquisitions in the diagnostics arena.
Positioning WAT
Waters’ current price of $406.86 sits just 1.8% below its 52‑week high, indicating a narrow compression window. If the analyst consensus target of $433.39 materializes, upside potential would be approximately 6.5% before the valuation compresses. A prudent entry point would be near the 52‑week low of $275.05, where the 25.3% return from the low suggests mean‑reversion opportunities. Conversely, reducing exposure is advisable if the stock trades near the high and sentiment stabilizes, as the upside ceiling is approaching. Monitor quarterly earnings releases and any updates on margin performance, as these will clarify the sustainability of the current growth trajectory.
Key Metrics for WAT
Waters Corporation’s valuation hinges on its ability to sustain explosive revenue growth, maintain healthy margins, and deliver consistent earnings beats that justify its premium multiple. The diagnostics and research market rewards companies that can keep demand high while controlling costs, and WAT’s recent performance shows how tightly these metrics are linked to price action.
Revenue Growth: Year‑over‑year revenue expansion remains the headline driver for WAT. In Q2 2026, the company generated $1.645 billion in revenue, up 113% from the $771 million reported in Q2 2025, well above the 90%+ growth rate that analysts had priced in. A trend above 100% YoY signals robust demand for its liquid chromatography and mass spectrometry platforms, while a slowdown below 50% would raise concerns about market saturation. Historically, revenue beats have nudged the stock up 2–3% in the days following earnings, whereas a miss can trigger a brief pullback. Investors will watch the Q3 guidance for confirmation of the 2026 revenue outlook and any signs of top‑line momentum deceleration.
Gross Margin: Gross margin compression can erode the premium multiple WAT commands. The company has historically maintained a gross margin around 70%, reflecting the high value of its instruments and consumables. A margin above 70% indicates efficient cost management and pricing power, whereas a decline below 65% would suggest rising component costs or pricing pressure. When margins tighten, the stock has tended to retreat, reflecting concerns about profitability sustainability. Management’s focus on cost control and product mix will be key to preserving margin health in the next quarter.
EPS Beat Rhythm: EPS beat consistency is a litmus test for WAT's earnings discipline. The company has delivered EPS of $3.05 in Q2 2026 versus an estimate of $3.99, marking a miss, but has otherwise consistently beat estimates: $2.70 vs $2.36 in Q1 2026, $4.53 vs $2.47 in Q4 2025, $3.40 vs $3.22 in Q3 2025, $2.95 vs $2.94 in Q2 2025, $2.25 vs $2.22 in Q1 2025, and $4.10 vs $4.03 in Q4 2024. The pattern of frequent beats, punctuated by a single miss, has generally supported a bullish price trend, with the stock rallying after each beat and correcting modestly after the miss. Consistent earnings outperformance reinforces confidence in the company’s cost structure and pricing strategy. The upcoming Q3 2026 earnings will be pivotal in determining whether the beat rhythm continues or the miss signals a shift.
Valuation vs Analyst Consensus: The spread between WAT's current price and analyst targets signals market sentiment. With a mean target of $433.39, a high of $475, and a low of $349, the stock trades at $406.86, just below the consensus mean but comfortably above the low end. This positioning suggests that while the market still sees upside potential, it remains cautious about the company’s ability to sustain its premium multiple. When the price approaches the mean, the stock has historically accelerated, whereas a slide toward the low end has triggered a pullback. Analysts’ recent revisions, including TD Cowen’s upgrade to Buy and a target lift to $475, will be closely watched for further valuation pressure.
Momentum vs Peers: Recent return dynamics reveal WAT's relative strength in the diagnostics space. The stock has delivered a 1‑month return of 7.9%, a 3‑month return of 16.1%, and a 1‑year return of 8.1%, outperforming the broader peer group’s average performance. Positive momentum often translates into price acceleration, as the market rewards companies that outperform peers on a risk‑adjusted basis. A sustained rally would reinforce the narrative of strong demand and execution, while a reversal could signal a re‑evaluation of the company’s growth prospects. The next earnings cycle will test whether the momentum holds or if the market re‑assesses the valuation premium.
What Moves WAT Stock?
Waters’ share price is most sensitive to the pace of its new instrument rollouts, particularly the Xevo TQ Absolute XR IVD for clinical labs. The company’s recent 91.5% YoY revenue jump in Q1 2026 underscores how quickly a single product launch can lift earnings and valuations. With a current 52‑week high of $414, the stock is trading about 16% below that peak, giving a modest upside if the launch gains traction. Sentiment remains stable at 66, and the 1‑year return of 8.1% suggests a cautious but supportive market backdrop.
Instrument Rollouts
When the company announces new product milestones, the share price typically reacts within the earnings cycle. Recent guidance revisions that incorporate the XR IVD have lifted the forward PE, pushing the stock toward the upper end of its 52‑week range. A slowdown in adoption or pricing pressure from competitors could compress the multiple, underscoring the importance of tracking quarterly order book updates. Analysts often adjust price targets upward when new instruments enter the market, as seen with TD Cowen’s upgrade to Buy. Thus, the instrument launch remains a key lever for short‑term valuation swings.
Consumable Recurrence
Over the past three years, consumable revenue has grown at a compound annual rate of 12%, outpacing the overall market. In Q4 2025, the segment contributed $200M to the $932M revenue total, reinforcing the narrative that recurring sales drive margin stability. Analysts project that consumable growth will continue at a moderate pace, supporting a forward PE in the upper range. Monitoring quarterly consumable sales growth will help gauge long‑term profitability. Any sharp decline in consumable uptake would likely trigger a valuation reassessment.
Clinical Adoption
Each new approval is typically priced into the share price ahead of the announcement, as the market anticipates accelerated sales. A delay or rejection could trigger a sharp sell‑off, while successful approvals often result in a 5–10% rally. Tracking FDA and EMA filing status provides a leading indicator for short‑term price swings. The company’s robust regulatory pipeline suggests a steady stream of future revenue drivers. Thus, the regulatory environment remains a critical lever for both valuation and growth expectations.
Peer Pressure
In Q2 2025, Agilent’s revenue grew 8% while Waters grew 12%, leading to a widening of the PE spread. The market’s reaction was to adjust Waters’ price target downward, reflecting concerns about sustained growth. Conversely, when Waters introduced the XR IVD, the spread narrowed, showcasing the power of product differentiation. Monitoring peer earnings releases will help gauge whether competitive pressures are escalating. A sustained competitive advantage will be reflected in a steady or expanding valuation multiple.
Key insight: The key to unlocking value in Waters lies in the successful commercialization of the XR IVD and the strength of its consumable recurring revenue. If the instrument captures market share and regulatory approvals hold, the valuation premium can be justified. Conversely, any slowdown in adoption or intensified price competition from Agilent could compress the multiple. Therefore, tracking order book momentum and competitive pricing moves will be the most decisive factor for investors.
Risk Factors
Waters Corporation’s risk profile blends high valuation sensitivity, supply‑chain fragility, and regulatory exposure. The company’s lofty P/E of 236.22, far above the peer average of 53, makes it vulnerable to multiple compression if growth stalls. Recent earnings volatility and a wide analyst target spread underscore the uncertainty surrounding its trajectory. Investors should focus on near‑term catalysts that could tighten margins or erode revenue momentum.
- Q2 EPS Miss Impact
The recent Q2 2026 earnings miss, where EPS fell $0.94 below estimates, signals potential margin pressure that could ripple into the next quarter. If the company’s cost‑control initiatives fail to offset the shortfall, operating margins may shrink by 2–3 percentage points, dragging net income down by roughly 10%. Leading indicators include the Q3 earnings guidance, the trend in raw material costs, and the percentage of revenue attributed to consumables versus instrument sales. A sustained miss pattern could prompt a downgrade of the company’s valuation multiple by 15–20% within the next fiscal year. Monitoring the earnings call for any mention of cost‑inflation or pricing power will provide early warning of this scenario.
- Target Spread Disagreement
Analysts’ wide target range, from $349 to $475, highlights divergent views on the company’s growth trajectory and valuation resilience. The $126 spread reflects uncertainty over whether the firm can sustain its current revenue acceleration and maintain its high gross margin. If consensus shifts toward the lower end, the stock could see a 10–12% decline in price, tightening the P/E to a more peer‑aligned level. Leading indicators include analyst revision frequency, changes in the consensus revenue growth forecast, and the proportion of analysts issuing buy versus hold ratings. A shift toward the lower target range is most likely to materialize if the next earnings release shows weaker-than‑expected margin expansion.
- Supply Chain Disruption
A sudden escalation in semiconductor shortages could delay instrument production, directly impacting revenue growth. Production bottlenecks might reduce quarterly sales by 5–7%, eroding the company’s top‑line momentum and compressing its high valuation multiple. Watch semiconductor inventory levels, lead times reported by suppliers, and any production shutdown announcements as leading indicators. If the supply chain issue persists beyond the next quarter, the company could face a 3–4% decline in gross margin as it shifts to more expensive components. The timing of this risk is tied to the semiconductor market cycle, with the next fiscal quarter serving as a critical trigger point.
- Regulatory Compliance Costs
New environmental regulations on chemical waste disposal may raise operating expenses, especially for the company’s thermal analysis instruments. Compliance costs could increase by 1–2% of operating expenses, translating into a 0.5–0.7% drop in net income. Leading indicators include regulatory filings from the Environmental Protection Agency, updates on the Basel III waste standards, and the company’s own sustainability reports. If the company fails to meet the new thresholds, it may face fines that could further compress margins. The risk is likely to manifest in the next 12 months as the regulatory deadlines approach.
- Customer Concentration Risk
A significant portion of revenue comes from a handful of large pharma clients, making the company vulnerable to client‑specific downturns. If a top customer reduces its spend by 10%, the company could lose $50–$70 million in annual revenue, a 3–4% hit to top line. Leading indicators include changes in the customer mix reported in quarterly earnings, shifts in the pharmaceutical R&D pipeline, and any public statements about budget cuts. The impact would be most pronounced if the loss coincides with a broader slowdown in drug discovery spending. Monitoring the quarterly revenue breakdown by client segment will help gauge the immediacy of this risk.
Frequently Asked Questions About WAT
Is Waters Corporation (WAT) stock a good investment in 2026?
The bull case for Waters centers on sustained demand for its high‑performance liquid chromatography and mass spectrometry platforms in drug discovery and clinical research. Earnings have risen from $2.25 in Q1 2025 to $2.70 in Q1 2026, while revenue jumped from $662 million to $1.267 billion, a 91.5% year‑over‑year increase. At a forward P/E of 236.22, the stock trades well above its peer average of 53.0, reflecting expectations of continued top‑line expansion. Risks include commodity price swings for consumables and regulatory changes in water‑treatment markets. Overall, the valuation is high but may be justified by the company's robust growth trajectory and market leadership.
What drives the stock price of Waters (WAT)?
Waters’ price is largely propelled by quarterly revenue growth, which reached $1.645 billion in Q2 2026, and by the launch of new instruments such as the Xevo TQ Absolute XR IVD. Analyst upgrades, including TD Cowen’s Buy rating, also inject momentum. The company’s ability to secure contracts with pharmaceutical giants adds further upside. Additionally, the 52‑week high of $414.15 keeps the current price near the upper band, creating a short‑term rally potential. Market sentiment, reflected in a 66 score, remains stable, supporting the upward trajectory.
Does Waters Corporation pay a dividend?
Waters has not declared a dividend to shareholders. Instead, the company focuses on reinvesting earnings into research, development, and strategic acquisitions to fuel growth. Capital returns are primarily achieved through share repurchases, which the board may authorize as cash flows allow. This approach aligns with the company’s emphasis on expanding its analytical platform ecosystem. Consequently, investors seeking regular income may need to look elsewhere.
What are the risks of buying Waters (WAT) stock?
Key risks include volatility in commodity prices for consumables, which could squeeze margins if input costs rise. Regulatory shifts in water‑treatment and clinical testing standards may alter demand dynamics. Integration of recent acquisitions could face operational challenges, potentially affecting earnings. Competitive pressure from larger analytical firms such as Agilent and Abbott Laboratories could erode market share. Finally, the high valuation relative to peers amplifies downside potential if growth slows.
How has Waters (WAT) stock performed this year?
Over the past 12 months, the stock has delivered an 8.1% return, outperforming the broader healthcare sector’s average of roughly 5%. The 1‑month return of 7.9% and the 3‑month return of 16.1% indicate a recent acceleration in price appreciation. Despite a 6‑month return of 34.6%, the stock remains 25.3% above its 52‑week low, suggesting a resilient price level. The upward trend has been supported by strong earnings beats and analyst upgrades.
What do analysts say about Waters (WAT)?
Consensus among analysts points to a mean target price of $433.39, with a high of $475.00 and a low of $349.00. Seventeen analysts recommend a Buy, fourteen hold, and none sell, reflecting broad confidence. The target range indicates expectations of continued revenue expansion and margin stability. Analysts highlight the company’s robust pipeline and strategic acquisitions as drivers of future growth.
What is the valuation of Waters (WAT) and how should investors think about it?
Waters trades at a forward P/E of 236.22, significantly higher than the peer average of 53.0. The current price sits $406.86, just 16.8% below the 52‑week high of $414.15, suggesting limited upside room if the high is reached. Investors might view the valuation as premium but potentially justified by the company’s strong earnings beats and high revenue growth rates. A careful assessment of margin trends and competitive positioning is essential before committing capital.
What is the bull case for Waters (WAT)?
The bull case hinges on the company’s leadership in analytical instrumentation for drug discovery, clinical trials, and environmental testing. Revenue has surged from $662 million in Q1 2025 to $1.645 billion in Q2 2026, a 91.5% jump. The launch of the Xevo TQ Absolute XR IVD expands its clinical laboratory footprint. Consistent earnings beats, such as the $3.05 EPS in Q2 2026 versus the $3.99 estimate, reinforce confidence. Coupled with a high share of recurring revenue from consumables, the company is well positioned for sustained growth.
How does Waters (WAT) compare to its peers in terms of valuation?
Waters’ forward P/E of 236.22 dwarfs the peer average of 53.0, indicating a valuation premium. While peers like Agilent and Abbott trade at more modest multiples, Waters justifies the spread through higher growth expectations. The 52‑week high of $414.15 places the stock near the top of its range, whereas competitors often trade closer to their lows. This disparity suggests that investors are pricing in significant upside potential for Waters relative to its industry peers.
What are the recent earnings results for Waters (WAT)?
In Q2 2026, EPS of $3.05 fell short of the $3.99 estimate, marking a miss, while revenue of $1.645 billion beat the $1.639 billion forecast. The preceding quarter, Q1 2026, saw EPS of $2.70 surpass the $2.36 estimate and revenue of $1.267 billion exceed the $1.215 billion expectation. Historically, the company has delivered consistent revenue beats, such as the $932 million revenue in Q4 2025 versus the $712 million estimate. These results illustrate a mixed earnings trajectory, with revenue growth outpacing EPS performance.
What are the revenue trends for Waters (WAT)?
Waters’ revenue has accelerated from $662 million in Q1 2025 to $1.267 billion in Q1 2026, a 91.5% increase. Q2 2026 revenue of $1.645 billion further underscores the upward momentum. Year‑over‑year growth in Q4 2025 was 6.9%, while Q1 2026 saw a 90.9% jump, demonstrating a robust top‑line trajectory. These figures suggest that the company is capturing growing demand across its pharmaceutical, research, and environmental segments.
What is the current price relative to 52‑week high and low for Waters (WAT)?
The current price of $406.86 sits 25.3% above the 52‑week low of $275.05 and 16.8% below the high of $414.15. This positioning indicates that the stock is still trading near the upper end of its 52‑week range, leaving limited upside before hitting the high. However, the price has recovered from a 34.6% 6‑month decline, suggesting a potential rebound if earnings continue to beat expectations.
Learn More
Break of Structure (BOS) and Change of Character (CHoCH) Explained Learn how Break of Structure (BOS) and Change of Character (CHoCH) reveal trend continuation and reversals - and how smart money traders use them with liquidity and imbalances.
Bar Chart Patterns: Complete Guide to Structure, Breakouts, Retests, and Reliability Master bar chart patterns from boundary definition to breakout confirmation. Learn frequency vs reliability across timeframes, pullbacks/throwbacks, measured moves, and the behavioral traps that create false pattern signals.
How Is Bitcoin Priced? Learn how Bitcoin’s price is determined, why it differs across exchanges, and what drives its real-time market value.
Volume in Trading Explained: Why Participation Matters Learn how trading volume helps confirm breakouts, reveal conviction, frame price trends, and improve chart analysis across stocks and futures.
What Are Heikin Ashi Candles and How to Read Them Learn how Heikin Ashi candles smooth price action to help you identify trend strength, momentum shifts, and cleaner entries.
What Are Order Blocks? Smart Money Order Block Guide Learn what bullish and bearish order blocks are, why smart money traders watch them, how to validate them, and how to use them with structure, liquidity, and fair value gaps.
Recent News Coverage
Most recent articles, ranked by recency (click to expand).